Search Result

Results for "

modest

" in MedChemExpress (MCE) Product Catalog:

By Targets:	AAK1 (1) Adenylate Cyclase (1) Adrenergic Receptor (4) Antibiotic (2) Apoptosis (4) Autophagy (2) BCRP (1) Btk (1) Cannabinoid Receptor (1) Caspase (1) CDK (1) Cyclin G-associated Kinase (GAK) (1) EGFR (1) Endogenous Metabolite (2) Epigenetic Reader Domain (1) FGFR (2) Fungal (1) Glucocorticoid Receptor (2) GSK-3 (1) HIF/HIF Prolyl-Hydroxylase (1) Histone Demethylase (1) iGluR (1) Isotope-Labeled Compounds (1) JAK (1) NO Synthase (1) Parasite (1) PARP (9) Phosphatase (1) PI3K (2) Potassium Channel (1) SARS-CoV (1) Sodium Channel (1) Thyroid Hormone Receptor (1) URAT1 (1) VEGFR (1)
By Research Areas:	Cancer (21) Cardiovascular Disease (2) Endocrinology (6) Infection (4) Inflammation/Immunology (7) Metabolic Disease (3) Neurological Disease (13)

By Targets:

AAK1 (1)

Adenylate Cyclase (1)

Adrenergic Receptor (4)

Antibiotic (2)

Apoptosis (4)

Autophagy (2)

BCRP (1)

Btk (1)

Cannabinoid Receptor (1)

Caspase (1)

CDK (1)

Cyclin G-associated Kinase (GAK) (1)

EGFR (1)

Endogenous Metabolite (2)

Epigenetic Reader Domain (1)

FGFR (2)

Fungal (1)

Glucocorticoid Receptor (2)

GSK-3 (1)

HIF/HIF Prolyl-Hydroxylase (1)

Histone Demethylase (1)

iGluR (1)

Isotope-Labeled Compounds (1)

JAK (1)

NO Synthase (1)

Parasite (1)

PARP (9)

Phosphatase (1)

PI3K (2)

Potassium Channel (1)

SARS-CoV (1)

Sodium Channel (1)

Thyroid Hormone Receptor (1)

URAT1 (1)

VEGFR (1)

By Research Areas:

Cancer (21)

Cardiovascular Disease (2)

Endocrinology (6)

Infection (4)

Inflammation/Immunology (7)

Metabolic Disease (3)

Neurological Disease (13)

Inhibitors & Agonists

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P1095

Ivachtin Caspase-3 Inhibitor VII	Caspase	Cardiovascular Disease Neurological Disease
Ivachtin (Caspase-3 Inhibitor VII; compound 7a) is a nonpeptide, noncompetitive and reversibl caspase-3 inhibitor with an IC₅₀ of 23 nM. Ivachtin has modest selectivity for the remaining caspases .

HY-B1618S1

Corticosterone-d4	Glucocorticoid Receptor Endogenous Metabolite	Neurological Disease Endocrinology
Corticosterone-d₄ is the deuterium labeled Corticosterone. Corticosterone is an adrenocortical steroid that has modest but significant activities as a mineralocorticoid and a glucocorticoid.

HY-B1618S

Corticosterone-d8	Glucocorticoid Receptor Endogenous Metabolite	Neurological Disease Endocrinology
Corticosterone-d₈ is the deuterium labeled Corticosterone. Corticosterone is an adrenocortical steroid that has modest but significant activities as a mineralocorticoid and a glucocorticoid.

HY-N8386

Berkeleylactone F

Antibiotic Infection Cancer

Berkeleylactone F is an antibiotic macrolide compound. Berkeleylactone F showed modest inhibition of CCRF-CEM leukemia cells .

Berkeleylactone F	Antibiotic	Infection Cancer
Berkeleylactone F is an antibiotic macrolide compound. Berkeleylactone F showed modest inhibition of CCRF-CEM leukemia cells .

HY-117220

Aspochalasin M	Others	Cancer
Aspochalasin M is a colorless solid. Aspochalasin M shows modest activity against HL-60 cells with an IC₅₀ of 20.0 μM. Aspochalasin M has the potential for the research of leukemic disease .

HY-B1737

Pirenperone

R 47465

Pirenperone (R 47465) is a 5-HT₂ serotonin receptor antagonist. Pirenperone exhibits modest anxiolytic activity .
HY-163063

Antimalarial agent 34

Parasite Infection

Antimalarial agent 34 is a modest PfARK1/3 inhibitor and shows potent antiplasmodial activity (EC₅₀ = 0.16 μM) .
HY-13895

WHI-P154

1 Publications Verification

EGFR JAK Apoptosis Cancer

WHI-P154 is a potent EGFR inhibitor, and also modestly blocks JAK3, with IC₅₀s of 4 nM and 1.8 μM, respectively.

Pirenperone R 47465
Pirenperone (R 47465) is a 5-HT₂ serotonin receptor antagonist. Pirenperone exhibits modest anxiolytic activity .

Antimalarial agent 34	Parasite	Infection
Antimalarial agent 34 is a modest PfARK1/3 inhibitor and shows potent antiplasmodial activity (EC₅₀ = 0.16 μM) .

WHI-P154 1 Publications Verification	EGFR JAK Apoptosis	Cancer
WHI-P154 is a potent EGFR inhibitor, and also modestly blocks JAK3, with IC₅₀s of 4 nM and 1.8 μM, respectively.

HY-119529

Jineol 3,8-Quinolinediol	Others	Cancer
Jineol is a cytotoxic alkaloid from the centipede Scolopendra subspinipes. Jineol exhibits modest cytotoxic activity in vitro against the growth of human tumor cell lines .

HY-N3211

N-cis-Feruloyl tyramine cis-N-(4-Hydroxyphenethyl) ferulamide; cis-N-Feruloyltyramine	NO Synthase	Inflammation/Immunology
N-cis-Feruloyl tyramine (cis-N-(4-Hydroxyphenethyl) ferulamide) is a natural phenolic compound, exhibits modest inhibitory activity on LPS-activated NO production in RAW 264.7 cells .

HY-135236

OXFBD04	Epigenetic Reader Domain	Cancer
OXFBD04 is a potent and selective BRD4 inhibitor with an IC₅₀ of 166 nM. OXFBD04 is a potent BET bromodomain ligand with additional modest affinity for the CREBBP bromodomain. OXFBD04 has anti-cancer activity .

HY-50094

Pictilisib Maximum Cited Publications 42 Publications Verification GDC-0941	PI3K Autophagy Apoptosis	Cancer
Pictilisib (GDC-0941) is a potent inhibitor of PI3Kα/δ with an IC₅₀ of 3 nM, with modest selectivity against p110β (11-fold) and p110γ (25-fold).

HY-W013788

2-Palmitoylglycerol 2-Palm-Gl	Cannabinoid Receptor	Neurological Disease
2-Palmitoylglycerol (2-Palm-Gl), an congener of 2-arachidonoylglycerol (2-AG), is a modest cannabinoid receptor CB1 agonist. 2-Palmitoylglycerol also may be an endogenous ligand for GPR119 .

HY-N10229

Harzianum A	Fungal Antibiotic	Infection
Harzianum A is a trichothecene that isolated from the soil-borne fungus Trichoderma harzianum. Harzianum A shows no cytotoxicity against baby hamster kidney cells, no activity against Gram-negative and Gram-positive bacteria, but modest antifungal activity at 100 μg/mL .

HY-20180

Pictilisib dimethanesulfonate Maximum Cited Publications 42 Publications Verification GDC-0941 dimethanesulfonate; GDC-0941 2 MeSO3H salt	PI3K Autophagy Apoptosis	Cancer
Pictilisib dimethanesulfonate (GDC-0941 dimethanesulfonate) is a potent inhibitor of PI3Kα/δ with IC₅₀ of 3 nM, with modest selectivity against p110β (11-fold) and p110γ (25-fold).

HY-15641

FG-2216 3 Publications Verification IOX3; YM311	HIF/HIF Prolyl-Hydroxylase	Metabolic Disease
FG-2216 (IOX3) is a potent and orally active inhibitor of HIF prolyl hydroxylase-2 (PHD2), with an IC₅₀ of 3.9 μM. FG-2216 induces robust erythropoietin and modest fetal hemoglobin in vivo .

HY-108631

EB-47 dihydrochloride 2 Publications Verification	PARP	Inflammation/Immunology
EB-47 dihydrochloride, a potent and selective PARP-1/ARTD-1 inhibitor with an IC₅₀ value of 45 nM, shows modest potency against ARTD5 with an IC₅₀ value of 410 nM. EB-47 mimics the substrate NAD ⁺ and extends from the nicotinamide to the adenosine subsite .

HY-15046

EB-47	PARP	Cardiovascular Disease Inflammation/Immunology
EB-47, a potent and selective PARP-1/ARTD-1 inhibitor with an IC₅₀ value of 45 nM, shows modest potency against ARTD5 with an IC₅₀ value of 410 nM. EB-47 mimics the substrate NAD ⁺ and extends from the nicotinamide to the adenosine subsite .

HY-111345

Epaminurad UR-1102; URC-102	URAT1	Metabolic Disease Inflammation/Immunology
Epaminurad (UR-1102) is an orally active, potent and selective URAT1 (urate transporter 1) inhibitor, with a K_i of 0.057 μM. Epaminurad quite modestly inhibits OAT1 and OAT3 (organic anion transporter). Epaminurad is a uricosuric agent. Epaminurad can be used for gout and hyperuricemia research .

HY-10473

Eprotirome KB2115	Thyroid Hormone Receptor	Metabolic Disease Endocrinology
Eprotirome (KB2115) is a liver-selective thyroid hormone receptor (TR) agonist. KB2115 has modestly higher affinity for TRβ than for TRα. Eprotirome reduces low-density lipoprotein (LDL) cholesterol concentrations. Eprotirome can be used for dyslipidemias and obesity research .

HY-17034A

Dexmedetomidine hydrochloride 5+ Cited Publications (+)-Medetomidine hydrochloride; (S)-Medetomidine hydrochloride	Adrenergic Receptor	Neurological Disease Endocrinology Cancer
Dexmedetomidine hydrochloride ((+)-Medetomidine hydrochloride) is a potent, selective and orally active agonist of α2-adrenoceptor, with a K_i of 1.08 nM. Dexmedetomidine hydrochloride shows 1620-fold selectivity against α1-adrenoceptor. Dexmedetomidine hydrochloride exhibits anxiolysis, sedation, and modest analgesia effects .

HY-12719

Dexmedetomidine 5+ Cited Publications (+)-Medetomidine; (S)-Medetomidine	Adrenergic Receptor	Neurological Disease Cancer
Dexmedetomidine ((+)-Medetomidine) is a potent, selective and orally active agonist of α2-adrenoceptor, with a K_i of 1.08 nM. Dexmedetomidine shows 1620-fold selectivity against α1-adrenoceptor. Dexmedetomidine exhibits anxiolysis, sedation, and modest analgesia effects .

HY-145830

AC1-IN-1	Adenylate Cyclase	Neurological Disease
AC1-IN-1 is a potent and selective Adenylyl cyclase type 1 (AC1) inhibitor with an IC₅₀ of 0.54 µM. AC1-IN-1 displays modest antiallodynic effects in a mouse model of inflammatory pain. AC1-IN-1 has CNS activity .

HY-133146

DJ001	Phosphatase Apoptosis	Inflammation/Immunology
DJ001 is a highly specific, selective and non-competitive protein tyrosine phosphatase-σ (PTPσ) inhibitor with an IC₅₀ of 1.43 μM. DJ001 displays no inhibitory activity against other phosphatases, with only modest inhibitory activity against Protein Phosphatase 5. DJ001 promotes promote hematopoietic stem cell regeneration .

HY-10617

Rucaparib phosphate 30+ Cited Publications AG-014699 phosphate; PF-01367338 phosphate	PARP	Cancer
Rucaparib (AG014699) phosphate is an orally active, potent inhibitor of PARP proteins (PARP-1, PARP-2 and PARP-3) with a K_i of 1.4 nM for PARP1. Rucaparib phosphate is a modest hexose-6-phosphate dehydrogenase (H6PD) inhibitor. Rucaparib phosphate has the potential for castration-resistant prostate cancer (CRPC) research .

HY-10617A

Rucaparib 30+ Cited Publications AG014699; PF-01367338	PARP	Cancer
Rucaparib (AG014699) is an orally active, potent inhibitor of PARP proteins (PARP-1, PARP-2 and PARP-3) with a K_i of 1.4 nM for PARP1. Rucaparib is a modest hexose-6-phosphate dehydrogenase (H6PD) inhibitor. Rucaparib has the potential for castration-resistant prostate cancer (CRPC) research .

HY-10617D

Rucaparib acetate AG014699 acetate; PF-01367338 acetate	PARP	Cancer
Rucaparib (AG014699) acetate is an orally active, potent inhibitor of PARP proteins (PARP-1, PARP-2 and PARP-3) with a K_i of 1.4 nM for PARP1. Rucaparib acetate is a modest hexose-6-phosphate dehydrogenase (H6PD) inhibitor. Rucaparib acetate has the potential for castration-resistant prostate cancer (CRPC) research .

HY-10617B

Rucaparib hydrochloride AG014699 hydrochloride; PF-01367338 hydrochloride	PARP	Cancer
Rucaparib (AG014699) hydrochloride is an orally active, potent inhibitor of PARP proteins (PARP-1, PARP-2 and PARP-3) with a K_i of 1.4 nM for PARP1. Rucaparib hydrochloride is a modest hexose-6-phosphate dehydrogenase (H6PD) inhibitor. Rucaparib hydrochloride has the potential for castration-resistant prostate cancer (CRPC) research .

HY-18010

PCI 29732 3 Publications Verification	Btk BCRP	Inflammation/Immunology
PCI 29732 is a potent, orally active, reversible BTK inhibitor with K_i ^app values of 8.2, 4.6, and 2.5 nM for BTK, Lck and Lyn, respectively. PCI 29732 shows only modest inhibitory activity against Itk, another Tec family kinase. PCI 29732 inhibits the function of ABCG2 by competitively binding to the ATP-binding site of ABCG2 .

HY-102003

Rucaparib monocamsylate 2 Publications Verification AG014699 monocamsylate; PF-01367338 monocamsylate	PARP	Cancer
Rucaparib (AG014699) monocamsylate is an orally active, potent inhibitor of PARP proteins (PARP-1, PARP-2 and PARP-3) with a K_i of 1.4 nM for PARP1. Rucaparib monocamsylate is a modest hexose-6-phosphate dehydrogenase (H6PD) inhibitor. Rucaparib monocamsylate has the potential for castration-resistant prostate cancer (CRPC) research .

HY-112705

VU0529331	Potassium Channel	Neurological Disease
VU0529331 is a modestly selective non-GIRK1-containing G protein-gated, inwardly-rectifying, potassium channel (non-GIRK1/X) activator, with EC₅₀s of 5.1 µM and 5.2 µM for GIRK2 and GIRK1/2 in HEK293 cells, respectively, also effective on GIRK4 homomeric channel .

HY-102003A

Rucaparib camsylate AG014699 camsylate; PF-01367338 camsylate	PARP	Cancer
Rucaparib (AG014699) camsylate is an orally active, potent inhibitor of PARP proteins (PARP-1, PARP-2 and PARP-3) with a K_i of 1.4 nM for PARP1. Rucaparib camsylate is a modest hexose-6-phosphate dehydrogenase (H6PD) inhibitor. Rucaparib camsylate has the potential for castration-resistant prostate cancer (CRPC) research .

HY-10617C

Rucaparib tartrate AG-014699 tartrate; PF-01367338 tartrate	PARP	Cancer
Rucaparib (AG014699) tartrate is an orally active, potent inhibitor of PARP proteins (PARP-1, PARP-2 and PARP-3) with a K_i of 1.4 nM for PARP1. Rucaparib tartrate is a modest hexose-6-phosphate dehydrogenase (H6PD) inhibitor. Rucaparib tartrate has the potential for castration-resistant prostate cancer (CRPC) research .

HY-17034AR

Dexmedetomidine hydrochloride (Standard) (+)-Medetomidine hydrochloride (Standard); (S)-Medetomidine hydrochloride (Standard)	Adrenergic Receptor	Neurological Disease Endocrinology Cancer
Dexmedetomidine (hydrochloride) (Standard) is the analytical standard of Dexmedetomidine (hydrochloride). This product is intended for research and analytical applications. Dexmedetomidine hydrochloride ((+)-Medetomidine hydrochloride) is a potent, selective and orally active agonist of α2-adrenoceptor, with a K_i of 1.08 nM. Dexmedetomidine hydrochloride shows 1620-fold selectivity against α1-adrenoceptor. Dexmedetomidine hydrochloride exhibits anxiolysis, sedation, and modest analgesia effects .

HY-17034AS

Dexmedetomidine-13C,d3 hydrochloride (+)-Medetomidine-¹³C,d₃ hydrochloride; (S)-Medetomidine-¹³C,d₃ hydrochloride	Isotope-Labeled Compounds Adrenergic Receptor	Neurological Disease Endocrinology Cancer
Dexmedetomidine- ¹³C,d₃ (hydrochloride) is the ¹³C- and deuterium labeled Dexmedetomidine (hydrochloride). Dexmedetomidine hydrochloride ((+)-Medetomidine hydrochloride) is a potent, selective and orally active agonist of α2-adrenoceptor, with a Ki of 1.08 nM. Dexmedetomidine hydrochloride shows 1620-fold selectivity against α1-adrenoceptor. Dexmedetomidine hydrochloride exhibits anxiolysis, sedation, and modest analgesia effects[1][2][3].

HY-100809

Guvacine hydrochloride
Guvacine hydrochloride is an alkaloid from the nut of Areca catechu, acts as an inhibitor of GABA transporter, and dispalys modest selectivity for cloned GABA transporters with IC₅₀s of 14 μM (human GAT-1), 39 μM (rat GAT-1), 58 μM (rat GAT-2), 119 μM (human GAT-3), 378 μM (rat GAT-3), and 1870 μM (human BGT-3).

HY-150619

KDM4-IN-4	Histone Demethylase	Cancer
KDM4-IN-4 (compound 47) is a potent histone lysine demethylase 4 (KDM4) inhibitor with a modest affinity binding to ~80 μM for KDM4A-Tudor domain. KDM4-IN-4 can inhibit H3K4Me3 binding to the Tudor domain in cells with an EC₅₀ value of 105 μM. KDM4-IN-4 can be used for researching anticancer .

HY-117626

LP-935509	AAK1 Cyclin G-associated Kinase (GAK) SARS-CoV	Infection Neurological Disease Inflammation/Immunology
LP-935509 is an orally active, potent, selective, ATP-competitive and brain-penetrant inhibitor of adaptor protein-2 associated kinase 1 (AAK1) with an IC₅₀ of 3.3 nM and a K_i of 0.9 nM, respectively. LP-935509 is also a potent inhibitor of BIKE (IC₅₀=14 nM) and a modest inhibitor of GAK (IC₅₀=320 nM). LP-935509 shows antinociceptive activity. LP-935509 can be used for neuropathic pain and SARS-CoV-2 research .

HY-126291

GNE-616	Sodium Channel	Neurological Disease
GNE-616 is a highly potent, metabolically stable, orally bioavailable, and subtype selective Nav1.7 inhibitor (K_i of 0.79 nM and K_d of 0.38 nM for hNav1.7) for the treatment of chronic pain. GNE-616 shows >1000 nM K_d and >2500-fold selectivity over hNav1.1, hNav1.3, hNav1.4, and hNav1.5. Selectivity over hNav1.2 and hNav1.6 is more modest at 31- and 73-fold, respectively .

HY-117734

PYD-106	iGluR	Neurological Disease
PYD-106 is a stereoselective pyrrolidinone (PYD) positive allosteric modulator for GluN2C-containing NMDA receptors. PYD-106 increases opening frequency and open time of single channel currents activated by maximally effective concentrations of agonist but only has modest effects on glutamate and glycine EC₅₀. PYD-106 selectively enhances the responses of diheteromeric GluN1/GluN2C receptors but not triheteromeric GluN1/GluN2A/GluN2C receptors .

HY-141685

3-Methylthienyl-carbonyl-JNJ-7706621	CDK GSK-3 VEGFR FGFR	Cancer
3-Methylthienyl-carbonyl-JNJ-7706621 is a potent and selective inhibitor of cyclin-dependent kinase (CDK), with IC₅₀s of 6.4 nM and 2 nM for CDK1/cyclin B and CDK2/cyclin A, respectively. 3-Methylthienyl-carbonyl-JNJ-7706621 also shows potent inhibition of GSK-3 (IC₅₀=0.041 μM) and modest potency against CDK4, VEGF-R2, and FGF-R2 (IC₅₀=0.11, 0.13, 0.22 μM, respectively). 3-Methylthienyl-carbonyl-JNJ-7706621 can be used for the research of cancer .

HY-145836

FGFR4-IN-8	FGFR	Cancer
FGFR4-IN-8 (Compound 7v) is an ATP-competitive, highly selective covalent inhibitor of wild-type and gatekeeper mutant FGFR4. FGFR4-IN-8 exhibits excellent potency against FGFR4, FGFR4 ^V550L, FGFR4 ^V550M and FGFR4 ^C552S with IC₅₀s of 0.5, 0.25, 1.6, 931 nM, respectively. FGFR4-IN-8 exhibits potent antiproliferative activity against Hep3B hepatocellular carcinoma cells with the IC₅₀ value of 29 nM. FGFR4-IN-8 demonstrates modest in vivo antitumor efficacy in nude mice bearing the Huh-7 xenograft model .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-119529

Jineol 3,8-Quinolinediol	Alkaloids Classification of Application Fields Animals Source classification Quinoline Alkaloids Disease Research Fields Cancer	Others
Jineol is a cytotoxic alkaloid from the centipede Scolopendra subspinipes. Jineol exhibits modest cytotoxic activity in vitro against the growth of human tumor cell lines .

HY-W013788

2-Palmitoylglycerol 2-Palm-Gl	Natural Products Microorganisms Source classification Endogenous metabolite	Cannabinoid Receptor
2-Palmitoylglycerol (2-Palm-Gl), an congener of 2-arachidonoylglycerol (2-AG), is a modest cannabinoid receptor CB1 agonist. 2-Palmitoylglycerol also may be an endogenous ligand for GPR119 .

HY-N8386

Berkeleylactone F	Infection Structural Classification Microorganisms Classification of Application Fields Ketones, Aldehydes, Acids Source classification Disease Research Fields	Antibiotic
Berkeleylactone F is an antibiotic macrolide compound. Berkeleylactone F showed modest inhibition of CCRF-CEM leukemia cells .

HY-117220

Aspochalasin M	Alkaloids Microorganisms Pyrrole Alkaloids Classification of Application Fields Source classification Disease Research Fields Cancer	Others
Aspochalasin M is a colorless solid. Aspochalasin M shows modest activity against HL-60 cells with an IC₅₀ of 20.0 μM. Aspochalasin M has the potential for the research of leukemic disease .

HY-N3211

N-cis-Feruloyl tyramine cis-N-(4-Hydroxyphenethyl) ferulamide; cis-N-Feruloyltyramine	Structural Classification Annona cherimola Mill. Source classification Phenols Polyphenols Plants Annonaceae	NO Synthase
N-cis-Feruloyl tyramine (cis-N-(4-Hydroxyphenethyl) ferulamide) is a natural phenolic compound, exhibits modest inhibitory activity on LPS-activated NO production in RAW 264.7 cells .

HY-N10229

Harzianum A	Infection Microorganisms Classification of Application Fields Ketones, Aldehydes, Acids Source classification Disease Research Fields	Fungal Antibiotic
Harzianum A is a trichothecene that isolated from the soil-borne fungus Trichoderma harzianum. Harzianum A shows no cytotoxicity against baby hamster kidney cells, no activity against Gram-negative and Gram-positive bacteria, but modest antifungal activity at 100 μg/mL .

Cat. No.	Product Name	Chemical Structure

HY-B1618S1

Corticosterone-d4
Corticosterone-d₄ is the deuterium labeled Corticosterone. Corticosterone is an adrenocortical steroid that has modest but significant activities as a mineralocorticoid and a glucocorticoid.

HY-B1618S

Corticosterone-d8
Corticosterone-d₈ is the deuterium labeled Corticosterone. Corticosterone is an adrenocortical steroid that has modest but significant activities as a mineralocorticoid and a glucocorticoid.

HY-17034AS

Dexmedetomidine-13C,d3 hydrochloride

Dexmedetomidine- ¹³C,d₃ (hydrochloride) is the ¹³C- and deuterium labeled Dexmedetomidine (hydrochloride). Dexmedetomidine hydrochloride ((+)-Medetomidine hydrochloride) is a potent, selective and orally active agonist of α2-adrenoceptor, with a Ki of 1.08 nM. Dexmedetomidine hydrochloride shows 1620-fold selectivity against α1-adrenoceptor. Dexmedetomidine hydrochloride exhibits anxiolysis, sedation, and modest analgesia effects[1][2][3].

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks